Table 2.
Count (%)a | ||
---|---|---|
Publication year | 2016–2020 | 43 (49%) |
2011–2015 | 34 (39%) | |
2005–2010 | 11 (12%) | |
Quality appraisal (4* being lowest risk of bias) | 4* | 4 (4%) |
3* | 37 (42%) | |
2* | 33 (38%) | |
1* | 14 (16%) | |
Study type | Randomized controlled trial | 21 (24%) |
Nonrandomized controlled trial | 3 (3%) | |
Cohort study | 5 (6%) | |
Before and after study | 8 (9%) | |
Cross sectional study | 3 (3%) | |
Other quantitative study | 11 (12%) | |
Qualitative study | 27 (31%) | |
Mixed methods study | 10 (11%) | |
Continent | North America | 57 (65%) |
Europe | 26 (30%) | |
Asia | 4 (4%) | |
Australia | 1 (1%) | |
Setting | Hospital care (including secondary and tertiary settings) | 51 (58%) |
Outpatient care (including specialty and primary care settings) | 36 (41%) | |
Nursing home | 1 (1%) | |
Specialty area | Medication safety | 19 (22%) |
Diabetes | 17 (19%) | |
Cardiovascular | 15 (17%) | |
Respiratory | 6 (7%) | |
Oncology | 9 (10%) | |
Nephrology | 2 (2%) | |
Geriatrics | 4 (4%) | |
General medicine | 4 (4%) | |
Infectious disease | 11 (12%) | |
Surgery | 5 (6%) | |
Obstetrics | 1 (1%) | |
Pediatrics | 3 (3%) | |
Radiology | 4 (4%) | |
Psychiatry (including substance misuse) | 5 (6%) |
Counts may add to more than 100% where papers are in multiple categories.